Mizuho Securities analyst Uy Ear has reiterated their bullish stance on ARQT stock, giving a Buy rating yesterday. Uy Ear has given his Buy ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Arcutis Biotherapeutics (ARQT – Research Report) today and set a price target ...

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical foam 0.3%, and $2.5M for ZORYVE cream 0.15%; sales growth ...